Management of non-metastatic
castration-resistant
prostate cancer (nmCRPC) has undergone a paradigm shift with next-generation
androgen receptor inhibitors. However, direct comparative data are not available to inform treatment decisions and/or guideline recommendations. Therefore, we performed network meta-analysis to indirectly compare the efficacy and safety of currently available treatments. Multiple databases were searched for articles published before June 2020. Studies that compared overall and/or
metastasis-free and/or
prostate-specific antigen (PSA) progression-free survival (OS/MFS/PSA-PFS) and/or adverse events (AEs) in nmCRPC patients were considered eligible. Three studies (n = 4117) met our eligibility criteria. Formal network meta-analyses were conducted. For MFS,
apalutamide,
darolutamide, and
enzalutamide were significantly more effective than placebo, and
apalutamide emerged as the best option (P score: 0.8809).
Apalutamide [hazard ratio (HR): 0.85, 95% credible interval (CrI): 0.77-0.94] and
enzalutamide (HR: 0.86, 95% CrI: 0.78-0.95) were both significantly more effective than
darolutamide. For PSA-PFS, all three agents were statistically superior to placebo, and
apalutamide emerged as the likely preferred option (P score: 1.000).
Apalutamide (HR: 0.71, 95% CrI: 0.69-0.74) and
enzalutamide (HR: 0.76, 95% CrI: 0.74-0.79) were both significantly more effective than
darolutamide. For AEs (including all AEs, grade 3 or grade 4 AEs, grade 5 AEs, and discontinuation rates),
darolutamide was the likely best option.
Apalutamide and
enzalutamide appear to be more efficacious agents for
therapy of nmCRPC, while
darolutamide appears to have the most favorable tolerability profile. These findings may facilitate individualized treatment strategies and inform future direct comparative trials.